KIR2DS2

KIR2DS2 is an activating NK cell receptor that couples antigen recognition at the cell surface to NK cell cytotoxicity, signaling through the charged lysine in its transmembrane domain that recruits the DAP12 adaptor; a natural mutant disrupting this lysine loses DAP12 association and fails to trigger activation (PMID:11169398). Despite 99% extracellular identity with the inhibitory receptor KIR2DL2, KIR2DS2 does not bind HLA-Cw3, a divergence traced structurally to displacements at Tyr45 and Gln71 and interpreted as evolutionary selection for loss of C1 epitope recognition by the activating receptor (PMID:12668644, PMID:23189078). The complex structure with HLA-C*0102 shows that Tyr45 (versus Phe45 in inhibitory KIRs) dictates a distinct binding mode and that a conserved peptide 'AT' motif governs peptide-specific recognition (PMID:34967442). Functionally, KIR2DS2 directly recognizes conserved flaviviral superfamily 2 RNA helicase peptides (an 'MCHAT' motif) and an HCV helicase peptide presented by HLA-C*0102, activating NK cells and being sufficient to inhibit HCV and dengue virus replication (PMID:28916719), and it additionally recognizes a β2-microglobulin-independent ligand on cancer cells distinct from classical HLA-C ligands (PMID:28202613). KIR2DS2-mediated activation is integrated with co-expressed receptors: KIR2DL2 inhibition overrides it while KIR2DL1 is additive (PMID:24078689), and KIR2DS2+ NK cells display enhanced cytotoxicity against tumors, co-mediated by NKG2D and associated with elevated CD16 and ADCC (PMID:25381437, PMID:35768150).

1. 2000 High

   Established how KIR2DS2 converts ligand engagement into an activating signal, resolving why an inhibitory-like ectodomain produces stimulatory output.

   Evidence Sequence analysis of a natural transmembrane mutant, DAP12 co-transfection association, and NK cytotoxicity assays

   PMID:11169398

   Open questions at the time

   • Downstream DAP12 signaling intermediates not mapped in this study
   • Did not define the physiological ligand driving activation
2. 2003 High

   Explained at atomic resolution why activating KIR2DS2 fails to bind HLA-Cw3 despite near-identical ectodomain to inhibitory KIR2DL2, localizing the difference to two residues.

   Evidence 2.3-Å X-ray crystal structure plus KIR tetramer binding assays

   PMID:12668644

   Open questions at the time

   • Did not identify a positive ligand for KIR2DS2
   • Functional consequence of altered binding for NK activation not tested here
3. 2012 Medium

   Framed the loss of HLA-C binding as an evolutionary selection event rather than a degenerate accident, positioning KIR2DS2 as deliberately diverged from its inhibitory counterpart.

   Evidence Comparative genetics and evolutionary analysis with referenced tetramer binding data (review synthesis)

   PMID:23189078

   Open questions at the time

   • Inference rests on referenced prior structural/binding data
   • Does not establish the selective pressure or true activating ligand
4. 2013 Medium

   Defined how KIR2DS2 activation is integrated with co-expressed inhibitory and activating KIRs on the same NK cell, addressing the net functional output.

   Evidence NK clone functional assays against HLA-typed targets and KIR genotype–phenotype analysis in 159 donors

   PMID:24078689

   Open questions at the time

   • Molecular basis of inhibitory dominance not resolved
   • C1-reactivity readout did not identify the activating ligand at the molecular level
5. 2017 High

   Identified a physiological activating ligand—conserved flaviviral helicase peptides presented by HLA-C*0102—and linked KIR2DS2 recognition to antiviral control.

   Evidence Peptide-HLA binding, NK activation, endogenous presentation, and HCV/dengue replication inhibition assays

   PMID:28916719

   Open questions at the time

   • In vivo relevance during human infection not established
   • Affinity and structural basis of peptide recognition addressed only later
6. 2017 High

   Revealed a second, β2-microglobulin-independent ligand on cancer cells, distinguishing tumor recognition from classical HLA-C peptide presentation.

   Evidence KIR2DS2 reporter assays, β2-microglobulin siRNA knockdown, anti-class I antibody blocking, and trogocytosis analysis

   PMID:28202613

   Open questions at the time

   • Molecular identity of the non-classical ligand not determined
   • Binding affinity and structural basis of this interaction unknown
7. 2022 High

   Provided the structural rationale for KIR2DS2 peptide-specific recognition of HLA-C*0102, pinpointing Tyr45 and a peptide 'AT' motif as determinants of binding mode and specificity.

   Evidence 2.5-Å X-ray crystal structure of the KIR2DS2–HLA-C*0102 complex

   PMID:34967442

   Open questions at the time

   • Functional impact of the two binding orientations on signaling not tested
   • Does not address the non-HLA cancer ligand
8. 2014 Medium

   Showed KIR2DS2 marks functionally activated NK cells with enhanced antitumor cytotoxicity that is co-dependent on NKG2D ligands.

   Evidence FACS-sorted KIR2DS2+ NK subsets, in vitro cytotoxicity, NKG2D antibody blockade, and in vivo GBM xenografts

   PMID:25381437

   Open questions at the time

   • Cannot separate direct KIR2DS2 signaling from NKG2D contribution
   • Whether KIR2DS2 itself engaged a GBM ligand not defined
9. 2022 Medium

   Extended the antitumor phenotype across multiple malignancies and tied KIR2DS2 expression to elevated CD16 and antibody-dependent cytotoxicity transcriptional programs.

   Evidence Flow cytometry, bulk and single-cell RNA-seq, and NK activation assays with tumor targets and therapeutic antibodies

   PMID:35768150

   Open questions at the time

   • Causal mechanism linking KIR2DS2 to CD16/FCGR upregulation not established
   • Correlative association between KIR2DS2 expression and cytotoxic state
10. 2012 Low

    Linked KIR2DS2 surface expression to epigenetic control via promoter CpG methylation, addressing how its variegated expression is regulated.

    Evidence Bisulfite sequencing of a promoter CpG island and mRNA qPCR (n=20)

    PMID:22939905

    Open questions at the time

    • Correlational, not causal; no methylation manipulation to demonstrate control
    • Small sample size
    • Mechanism connecting demethylation to transcription not defined
11. 2011 Medium

    Characterized a recombinant KIR2DS2*005 fusion allele, defining allelic diversity at the locus and its effect on receptor architecture.

    Evidence cDNA sequencing, recombination mapping, population genetics, and dual-antibody surface expression analysis

    PMID:21593779

    Open questions at the time

    • Functional signaling consequence of the swapped transmembrane/cytoplasmic regions not tested
    • Ligand recognition by the fusion protein not assessed

• The molecular identity of the β2-microglobulin-independent cancer ligand and the in vivo contribution of KIR2DS2 to antiviral and antitumor immunity remain unresolved.
• Non-classical cancer ligand not biochemically identified
• Causal mechanism linking KIR2DS2 to CD16/ADCC programs unknown
• In vivo human relevance of helicase-peptide recognition untested